MAPT and Alzheimer disease: Palmqvist et al. (2019) found that CSF and plasma biomarkers of AD patients changed almost simultaneously. The study of Lue et al. (2017) revealed that compared with healthy older adults, aMCI patients had changes in their plasma Aβ42 and Tau levels and could reflect the progression of AD.